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Abstract
Background: Adolescents with type 1 diabetes (T1D) have 
increased risk of cardiovascular disease as well as eleva-
tions in biomarkers of systemic inflammation, plasma 
protein oxidation and vascular endothelial injury. It is 
unclear whether hyperglycemia itself, or variations in 
blood glucose are predictors of these abnormalities.
Methods: This study was designed to determine the rela-
tionship of inflammatory (C-reactive protein, CRP), oxida-
tive (total anti-oxidative capacity, TAOC) and endothelial 
injury (soluble intracellular adhesion molecule 1, sICAM1) 
markers to glycemic control measures from 3 days of con-
tinuous glucose monitoring (CGM) and to hemoglobin 
A1c (HbA1c), and HbA1c × duration area under the curve 
(A1cDur).
Results: Seventeen adolescents (8 F/9M; age, 
13.1 ± 1.6 years (mean±SD); duration, 4.8 ± 3.8 years, BMI, 
20.3 ± 3.1 kg/m2; A1c, 8.3 ± 1.2%) were studied. Log CRP 
but was not related to age, duration, body mass index 
(BMI), HbA1c, or A1cDUR. TAOC increased as logA1cDUR 
increased (n = 13, r = 0.61, p = 0.028). CRP and sICAM were 
not related to CGM average glucose but log CRP increased 
as 3 day glucose standard deviation increased (r = 0.66, 
p = 0.006). TAOC increased as glucose standard deviation 
increased (r = 0.63, p = 0.028).
Conclusions: Increased glucose variability is associated 
with increased inflammation in adolescents withT1D. 
Increased TAOC with increasing variability may be an 
effort to compensate for the ongoing oxidative stress.
Keywords: glucose variability; inflammation; oxidation; 
type 1 diabetes; vascular endothelial injury/stress. 
Introduction
Cardiovascular disease is the major cause of death for 
patients with type 1 diabetes (T1D) [1] and there is clear 
evidence that cardiovascular disease has its origins in 
childhood and adolescence [2–5]. Inflammation and vas-
cular endothelial injury are early events in nearly all forms 
of cardiovascular disease and several studies have shown 
that these biomarkers are also elevated in adolescents 
with type 1 diabetes prior to the clinical development of 
cardiovascular complications [6, 7]. Given the increased 
prevalence of T1D in children and its strong link to early 
heart disease in adulthood it is critical that we learn more 
about early predictors of complications and relationships 
among blood glucose abnormalities and biomarkers of 
disease processes to enable improved strategies for pre-
vention and/or therapy.
Current clinical management of T1D relies heavily on 
the average glycemia measure of hemoglobin A1c (HbA1c), 
but some very recent reports (mostly in adults) suggest that 
variations in blood glucose, rather than absolute or time-
averaged values, may be more strongly linked to unfavora-
ble outcomes. Specifically, in type 2 diabetes microvascular 
complications and coronary artery disease are consistently 
related to increased glucose variability although these 
relationship have not been found in adults with T1D [8]. 
Thus, the significance of increased glucose variability in 
T1D is controversial [9, 10]. Pathophysiologically, increased 
glucose variation may increase oxidative tissue damage 
more than continuous hyperglycemia [11, 12].
The goal of this study was to determine the relationship 
of biochemical inflammatory, oxidative, and endothelial 
markers to fasting glucose, 72 h mean glucose and glucose 
variability, HbA1c and HbA1c over time in adolescents with 
T1D. High sensitivity C-reactive protein (CRP) is the most 
studied inflammatory marker in pediatric type 1 diabetes. 
In healthy adults, CRP levels predict future cardiovascular 
disease and are linked to endothelial dysfunction [13–15], 
Most [6, 7, 16–22], but not all studies [23, 24], have dem-
onstrated significant increases in CRP levels in pediatric 
T1D patients. Soluble intracellular adhesion molecule 1 
(sICAM 1) is biochemical marker of endothelial damage 
and inflammation and is again elevated in  pediatric T1D 
[7, 20, 25–27].
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Materials and methods
Subjects
Seventeen adolescents (eight female, nine male) with T1D were 
recruited from the Pediatric Diabetes Clinic of Nationwide Children’s 
Hospital (NCH). The study was approved by the NCH Institutional 
Review Board and informed consent was obtained from parent or 
legal guardian. Proper assent was obtained from all subjects.
Screening included a history, physical exam, Tanner staging, 
and fasting laboratory testing. T1D was defined by American Diabe-
tes Association criteria plus a fasting C-peptide of <0.4 ng/mL, insu-
lin monotherapy since diagnosis, and an absence of a history of oral 
hypoglycemic agents and acanthosis nigricans on exam.
All subjects were Tanner stage 2–4 in order to minimize the 
effects of starting or finishing puberty. In order to limit confound-
ing effects on endothelial function, subjects with BP>95‰, smok-
ing, pregnancy, and uncorrected hypothyroidism, were excluded. 
Subjects with microalbuminuria, overt nephropathy, or early renal 
failure (random urine microalbumin/creatinine >0.02 mg albumin/
mg creatinine; serum creatinine >1.0 mg/dL) were, also, excluded.
Protocol
Subjects were admitted to the Clinical Research Center of the Wexner 
Medical Center at the Ohio State University at 07:30 after having 
fasted from 22:00 the night before. Subjects were instructed to take 
their usual basal insulin the night before or to remain on their usual 
basal insulin infusion rates if using continuous subcutaneous insu-
lin. Subjects withheld their morning insulin bolus until breakfast 
was given after the study completion. A blood sample was then col-
lected for measurement of fasting glucose and biochemical markers. 
Eleven patients then participated in an insulin clamp study to assess 
the effects of glucose normalization and hyperglycemia. Results 
on this study have been previously reported [28] as have results on 
endothelial function [29]. Subjects were then placed on a continuous 
glucose monitor (CGM, Medtronic Guardian, Fridley, MN, USA) for 
3 days after which the CGM was returned and the data downloaded 
using the Medtronic Carelink website to determine the mean glucose 
level and standard deviation.
Laboratory measurements
CRP, total plasma antioxidant capacity (TAOC), a measure of oxida-
tive stress, and sICAM1 were measured. TAOC is a non-specific assay 
of anti-oxidant defense which measures the ability of constituents 
in plasma to absorb oxidation (BioVision Research Products, Moun-
tain View, CA, USA). TAOC results were available in only 13 subjects. 
Serum sICAM levels were determined using a commercially available 
assay (R & D Systems, Minneapolis, MN, USA; Cat # BBE 1B).
Statistical analysis
Hemoglobin A1c by duration area under the curve (A1cDur) was cal-
culated using the trapezoidal rule. Pearson’s regression analysis was 
Table 1: Demographic and biochemical parameters.
Age, years   13.1 ± 1.6
Duration, years   4.8 ± 3.8
BMI, kg/m2   20.3 ± 3.1
Systolic pressure, mmHg   106 ± 6
Diastolic pressure, mmHg   61 ± 9
HbA1c,%   8.3 ± 1.2
Fasting glucose, mg/dL   160 ± 67
72 h mean glucose, mg/dL   200 ± 46
72 h glucose standard deviation, mg/dL   80 ± 20
C-reactive protein, ng/mL   1.45 ± 2.93
Soluble intracellular adhesion molecule, ng/mL  196 ± 80
Total anti-oxidant capacity, units   130 ± 40
Table 2: Correlation coefficient relationships of high sensitivity 
C-reactive protein (hsCRP), total anti-oxidant capacity (TAOC) and 
soluble intracellular adhesion molecule (sICAM) to age, duration, 
BMI, and glucose control variables in adolescent type 1 diabetes.
  LoghsCRP   TAOC   LogsICAM
Age   0.03   0.23   −0.36
Duration   0.42a   0.61b   0.24
BMI   0.34   0.22   −0.3
SBP   0.49a   0.08   0.44
DBP   0.18   −0.02   0.35
Fasting glucose   −0.11   0.16   −0.27
Log 72 h mean glucose   0.15   0.39   0.24
72 h standard deviation  0.66b   0.63a   0.46
Hemoglobin A1c   0.15   0.38   0.27
LogA1cAUC   0.39   0.61a   0.42
ap<0.05, bp<0.01.
used to assess the relationship between biochemical markers and 
the various measures of glucose control. Data was log normalized, as 
needed. All analysis was performed using Systat 13 (Systat Software 
Inc, Chicago, IL, USA). Results are reported as mean±SD.
Results
Age, duration, BMI effects and blood 
pressure effect
Mean demographic, glucose, and laboratory values for 
the subjects are shown in Table 1. Age and BMI were not 
significantly related to any of the measures (Table 2). Sys-
tolic blood pressure (SBP) but not diastolic pressure (DBP) 
increased as duration of diabetes increased (r = 0.62, 
p = 0.009). Neither was significantly related to age or BMI. 
TAOC increased as diabetes duration increased and logCRP 
tended to do the same. LogCRP increased as systolic blood 
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pressure increased and logsICAM tended to do the same. 
DBP was not related to hsCRP, TAOC, or sICAM.
Glucose control effects
SBP increased as logA1cDur increased (r = 0.63, p = 0.007) 
but was not related to any of the other glycemic control 
measures. DBP was not related to any of the glycemic 
control measures. HbA1c increased in older subjects 
(r = 0.55, p = 0.021).
LogCRP was not related to fasting glucose, 72 h mean 
glucose, HbA1c or A1cDur but was significant related to 
72 h glucose standard deviation (Figure 1). TAOC increased 
as logA1cDur increased as glucose standard deviation 
increased but was not related to the other measures. Log-
sICAM tended to increase as glucose standard deviation 
and A1cAUC increased.
Discussion
Our study is the first to report on the relationship of 
glucose variability to markers of inflammation, oxidation, 
and endothelial damage in adolescents with T1D. The 
results demonstrate that increasing glucose variability 
is associated with increasing inflammation as indicated 
by increasing levels of CRP. There was no relationship of 
inflammation to other measures of short, intermediate, 
or long-term glycemic control. Surprisingly, increased 
glucose variability was associated with increased, not 
decreased, TAOC. This may be compensation for increased 
oxidative stress. This hypothesis is supported by the posi-
tive relationships between TAOC and duration and A1cDur.
Hyperglycemia-induced oxidative stress plays a key 
role in increasing inflammation [30, 31]. Animal studies 
have suggested that intermittent hyperglycemia has a 
more pronounced effect than sustained hyperglycemia 
[10, 32, 33], although thus far human studies have been 
less convincing. We have previously found no relation-
ship between glucose variability and endothelial func-
tion or endothelial progenitor cells in adolescents with 
T1D [29]. In adults with T1D Gordin et al. [34] found no 
relationship between glucose variability and arterial 
stiffness and Cesana et  al. [35] found no relationship 
to carotid intimal thickness. No relationship was found 
between glucose variability and microvascular or macro-
vascular complications in the Diabetes Control and Com-
plications Trial [36–38]. Prospective studies have yielded 
variable results. In adults with T1D, Buse et al. [39] used 
sensor augmented pump therapy to reduce glucose vari-
ability in comparison to multiple daily injections and 
found a decrease in inflammatory ligand CD40L levels 
in the pump group but an increase in the injection group 
although the difference was not significant. In a single 
group study Dal et  al. [32] found no effect of flexible 
insulin therapy designed to reduce glucose variability 
although mean amplitude glucose excursion also did 
not change. Jamiolkowska et  al. [40] found that reduc-
ing glucose variability improved endothelial function in 
adolescents with T1D.
From our study it is unclear what the long-term effects 
of increased glucose variability and inflammation in ado-
lescent T1D will be. We found no relationship between 
glucose variability and blood pressure and subjects with 
evidence of early diabetes complications were excluded. 
We did find increased systolic blood pressure in subjects 
with long-standing poor diabetes control. We studied a 
small number of subjects so there may be additional rela-
tionships that were not detected. This is particularly true 
regarding sICAM were several of the correlation coeffi-
cients suggest possible relationships.
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Figure 1: Relationship of c-reactive protein (r = 0.63, p = 0.006), total anti-oxidant capacity (r = 0.63, p = 0.028) and soluble intracellular 
adhesion molecule(r = 0.46, p = 0.070) to 72 h glucose standard deviation in adolescents with type 1 diabetes.
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In conclusion, increased glucose variability in ado-
lescents with type 1 diabetes is associated with increased 
inflammation. Future longitudinal studies will be needed 
to explore the long term effects.
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